Literature DB >> 6652967

Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.

G Baatrup, I Petersen, J C Jensenius, S E Svehag.   

Abstract

Reduced complement-mediated solubilization (CMS) of pre-formed immune complexes (IC) was demonstrated in sera from 11 out of 12 SLE patients. The presence of incompletely solubilized endogeneous IC in SLE sera was indicated by the following findings: (1) When IC positive SLE sera with reduced CMS capacity were mixed with normal donor sera they inhibited the CMS of the latter sera. (2) Resuspended PEG (2.75%) precipitates obtained from SLE sera inhibited the CMS of normal donor sera. (3) Non-solubilized or incompletely complement solubilized IC in SLE sera give a strong response in the PEG-CC assay for IC. The IC activity of SLE sera was clearly reduced in this assay when the endogeneous IC were solubilized prior to testing. In contrast, sera of 14 rheumatoid arthritis (RA) patients exhibited normal CMS. IC which could be further solubilized by complement were not demonstrable although all RA sera were IC positive.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652967      PMCID: PMC1535882     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  A new complement function: solubilization of antigen-antibody aggregates.

Authors:  G W Miller; V Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

2.  Circulating immune complexes in systemic lupus erythematosus.

Authors:  P O Cano; L M Jerry; J P Sladowski; C K Osterland
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

3.  Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus.

Authors:  P Davis; R H Cumming; J Verrier-Jones
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

Review 4.  Mechanism of solubilization of immune aggregates by complement. Implications for immunopathology.

Authors:  M Takahashi; J Czop; A Ferreira; V Nussenzweig
Journal:  Transplant Rev       Date:  1976

5.  Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway.

Authors:  M Takahashi; S Takahashi; V Brade; V Nussenzweig
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

Review 6.  Solubilization of antigen-antibody complexes: a new function of complement as a regulator of immune reactions.

Authors:  M Takahashi; S Takahashi; S Hirose
Journal:  Prog Allergy       Date:  1980

7.  Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.

Authors:  C M Arroyave; M R Wilson; E M Tan
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

8.  Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus.

Authors:  C K Abrass; K M Nies; J S Louie; W A Border; R J Glassock
Journal:  Arthritis Rheum       Date:  1980-03

9.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

10.  Studies on the mechanism of solubilization of immune precipitates by serum.

Authors:  J Czop; V Nussenzweig
Journal:  J Exp Med       Date:  1976-03-01       Impact factor: 14.307

View more
  9 in total

1.  C3-containing serum immune complexes in patients with systemic lupus erythematosus: correlation to disease activity and comparison with other rheumatic diseases.

Authors:  C Huber; A Rüger; M Herrmann; F Krapf; J R Kalden
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

2.  Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation.

Authors:  A E Ahmed; J Veitch; K Whaley
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

3.  Clearance kinetics and organ uptake of complement-solubilized immune complexes in mice.

Authors:  M T Aguado; M Mannik
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

4.  Reduced complement-mediated immune complex solubilization in leprosy patients.

Authors:  V D Ramanathan; P Sharma; G Ramu; U Sengupta
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

5.  Complement-mediated solubilization of immune complexes. Solubilization inhibition and complement factor levels in SLE patients.

Authors:  G Baatrup; I Petersen; E Kappelgaard; H H Jepsen; S E Svehag
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

6.  Effects of coagulation temperature on measurements of complement function in serum samples from patients with systemic lupus erythematosus.

Authors:  G Baatrup; G Sturfelt; A Junker; S E Svehag
Journal:  Ann Rheum Dis       Date:  1992-07       Impact factor: 19.103

7.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  Precipitable immune complexes in healthy homosexual men, acquired immune deficiency syndrome and the related lymphadenopathy syndrome.

Authors:  H H Euler; P Kern; H Löffler; M Dietrich
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

9.  Inhibition of immune complex solubilization by sera of patients with membranoproliferative glomerulonephritis.

Authors:  T R Welch; A Kleesattel; L Beischel
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.